

Tine Baekdal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3040716/publications.pdf>

Version: 2024-02-01

14
papers

703
citations

932766

10
h-index

1125271

13
g-index

14
all docs

14
docs citations

14
times ranked

588
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 581-588.	2.2	36
2	Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1594-1603.	2.2	33
3	Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1171-1185.	1.6	10
4	Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 453-462.	0.8	15
5	Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1335-1348.	1.6	33
6	Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation. <i>Diabetes Therapy</i> , 2021, 12, 1915-1927.	1.2	15
7	Response to the letter from Horowitz et al. to the Editor relating to the publication "Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes" by Dahl et al.. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2414-2416.	2.2	0
8	Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration. <i>Diabetes Therapy</i> , 2021, 12, 2599-2610.	1.2	1
9	Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1139-1148.	1.5	11
10	Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1193-1203.	1.6	40
11	Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. <i>Clinical Pharmacokinetics</i> , 2019, 58, 781-791.	1.6	103
12	Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1314-1323.	1.0	60
13	Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	307
14	A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 869-877.	1.5	39